| Stock Price Performance - 12 Largest Positive Opening Gaps | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day of Event |
After Event Date (Not Including Day of Selected Event) |
||||||||||||||||
| Date | Note | Day-Of Move | Opening Gap | % Open-to-High | % Open-to-Low | Drift Open-to-Close | 1 Day | 2 Days | 3 Days | 1 Week | 2 Weeks | ||||||
| 14-Apr-2026 | +10.2% | ||||||||||||||||
| 10-Dec-2025 | +2.3% | ||||||||||||||||
| 18-Nov-2025 | +1.3% | ||||||||||||||||
| 13-Oct-2025 | Market Gap UpSPY had a large positive gap on the day of +1.2% | +1.3% | |||||||||||||||
| 9-May-2025 | +27.5% | ||||||||||||||||
| 10-Apr-2025 | -14.0% | ||||||||||||||||
| 24-Mar-2025 | Market Gap UpSPY had a large positive gap on the day of +1.2% | +19.3% | |||||||||||||||
| 5-Feb-2025 |
Press Release Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement (5-Feb-2025, 7:10 AM Business Wire) HeadlineAdicet Bio receives FDA fast track designation for its lupus erythematosus treatment (5-Feb-2025, 12:00 AM Seeking Alpha News) |
+9.8% | |||||||||||||||
| 8-Jul-2024 |
Press Release Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma (8-Jul-2024, 7:00 AM Business Wire) |
+9.3% | |||||||||||||||
| 23-Apr-2024 |
Press Release Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting (22-Apr-2024, 4:30 PM Business Wire) |
+5.0% | |||||||||||||||
| 4-Jan-2024 |
Press Releases Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook (3-Jan-2024, 4:01 PM Business Wire) Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 (4-Jan-2024, 7:00 AM Business Wire) |
+22.7% | |||||||||||||||
| 11-Dec-2023 |
Press Release Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting (10-Dec-2023, 12:00 PM Business Wire) |
-4.3% | |||||||||||||||
| Simple Average Returns - 12 Largest Positive Opening Gaps | |||||||||||||||||
| Avg Return | |||||||||||||||||
| Positive Occurrences | |||||||||||||||||
| Negative Occurrences | |||||||||||||||||
| Absolute Average Returns - 12 Largest Positive Opening Gaps | |||||||||||||||||
| Abs Avg Return | |||||||||||||||||
| Max Abs Return | |||||||||||||||||
| Min Abs Return | |||||||||||||||||
| Median, Minimum, and Maximum Returns - 12 Largest Positive Opening Gaps | |||||||||||||||||
| Median Return | |||||||||||||||||
| Max Positive Return | |||||||||||||||||
| Max Negative Return | |||||||||||||||||